Literature DB >> 27426424

Associations Between the Phosphatidylethanol Alcohol Biomarker and Self-Reported Alcohol Use in a Sample of HIV-Infected Outpatient Drinkers in Western Kenya.

Rebecca K Papas1, Benson N Gakinya2, Michael M Mwaniki3, Alfred K Keter3, Hana Lee4, Michelle P Loxley1, Debra A Klein5, John E Sidle6, Steve Martino7, Joyce B Baliddawa2, Kathryn L Schlaudt8, Stephen A Maisto9.   

Abstract

BACKGROUND: To counteract the syndemics of HIV and alcohol in Sub-Saharan Africa, international collaborations have developed interventions to reduce alcohol consumption. Reliable and accurate methods are needed to estimate alcohol use outcomes. A direct alcohol biomarker called phosphatidylethanol (PEth) has been shown to validate heavy, daily drinking, but the literature indicates mixed results for moderate and nondaily drinkers, including among HIV-infected populations. This study examined the associations of the PEth biomarker with self-report alcohol use at 2 time points in 127 HIV-infected outpatient drinkers in western Kenya.
METHODS: Participants were consecutively enrolled in a randomized clinical trial to test the efficacy of a behavioral intervention to reduce alcohol use in Eldoret, Kenya. They endorsed current alcohol use, and a minimum score of 3 on the Alcohol Use Disorders Identification Test-Consumption or consuming ≥6 drinks per occasion at least monthly in the past year. Study interviews and blood draws were conducted at baseline and at 3 months post treatment from July 2012 through September 2013. Alcohol use was assessed using the Timeline Followback questionnaire. Blood samples were analyzed for the presence of the PEth biomarker and were compared to self-reported alcohol use. We also conducted semistructured interviews with 14 study completers in February through March 2014.
RESULTS: Baseline data indicated an average of moderate-heavy alcohol use: 50% drinking days and a median of 4.5 drinks per drinking day. At baseline, 46% of women (31 of 67) and 8% of men (5 of 60) tested negative for PEth (p < 0.001). At the 3-month follow-up, 93% of women (25 of 27) and 97% of men (30 of 31) who reported drinking tested positive, while 70% of women (28 of 40) and 35% of men (10 of 29) who denied drinking tested negative for PEth. Interviews were consistent with self-reported alcohol use among 13 individuals with negative baseline results.
CONCLUSIONS: These results add to the growing literature showing lack of agreement between self-report and PEth results among unhealthy and nondaily drinkers, particularly women. More research is needed to determine at what level of consumption over what period of time PEth becomes a reliable and accurate indicator of alcohol use.
Copyright © 2016 by the Research Society on Alcoholism.

Entities:  

Keywords:  Alcohol; Biomarker; HIV; Kenya; PEth; Phosphatidylethanol

Mesh:

Substances:

Year:  2016        PMID: 27426424      PMCID: PMC4961598          DOI: 10.1111/acer.13132

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  38 in total

1.  Treatment outcomes of a stage 1 cognitive-behavioral trial to reduce alcohol use among human immunodeficiency virus-infected out-patients in western Kenya.

Authors:  Rebecca K Papas; John E Sidle; Benson N Gakinya; Joyce B Baliddawa; Steve Martino; Michael M Mwaniki; Rogers Songole; Otieno E Omolo; Allan M Kamanda; David O Ayuku; Claris Ojwang; Willis D Owino-Ong'or; Magdalena Harrington; Kendall J Bryant; Kathleen M Carroll; Amy C Justice; Joseph W Hogan; Stephen A Maisto
Journal:  Addiction       Date:  2011-08-18       Impact factor: 6.526

2.  Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar).

Authors:  J T Sullivan; K Sykora; J Schneiderman; C A Naranjo; E M Sellers
Journal:  Br J Addict       Date:  1989-11

3.  Normalization rate and cellular localization of phosphatidylethanol in whole blood from chronic alcoholics.

Authors:  A Varga; P Hansson; G Johnson; C Alling
Journal:  Clin Chim Acta       Date:  2000-09       Impact factor: 3.786

4.  Reliability of alcohol abusers' self-reports of drinking behavior.

Authors:  L C Sobell; S A Maisto; M B Sobell; A M Cooper
Journal:  Behav Res Ther       Date:  1979

5.  Correlation of ethanol concentrations in blood and saliva.

Authors:  K E McColl; B Whiting; M R Moore; A Goldberg
Journal:  Clin Sci (Lond)       Date:  1979-03       Impact factor: 6.124

6.  Alcohol abuse among patients with and without HIV infection attending public clinics in western Kenya.

Authors:  D N Shaffer; R Njeri; A C Justice; W W Odero; W M Tierney
Journal:  East Afr Med J       Date:  2004-11

7.  Substance abuse in outpatients attending rural and urban health centres in Kenya.

Authors:  C J Othieno; D M Kathuku; D M Ndetei
Journal:  East Afr Med J       Date:  2000-11

8.  Case-crossover study of partner and situational factors for unprotected sex.

Authors:  George R Seage; Sarah Holte; Michael Gross; Beryl Koblin; Michael Marmor; Kenneth H Mayer; William R Lenderking
Journal:  J Acquir Immune Defic Syndr       Date:  2002-12-01       Impact factor: 3.731

9.  Comparison of self-reported alcohol consumption to phosphatidylethanol measurement among HIV-infected patients initiating antiretroviral treatment in southwestern Uganda.

Authors:  Francis Bajunirwe; Jessica E Haberer; Yap Boum; Peter Hunt; Rain Mocello; Jeffrey N Martin; David R Bangsberg; Judith A Hahn
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

10.  Efficacy of an alcohol-focused intervention for improving adherence to antiretroviral therapy (ART) and HIV treatment outcomes - a randomised controlled trial protocol.

Authors:  Charles Dh Parry; Neo K Morojele; Bronwyn J Myers; Connie T Kekwaletswe; Samuel O M Manda; Katherine Sorsdahl; Gita Ramjee; Judith A Hahn; Jürgen Rehm; Paul A Shuper
Journal:  BMC Infect Dis       Date:  2014-09-12       Impact factor: 3.090

View more
  24 in total

1.  Phosphatidylethanol in Comparison to Self-Reported Alcohol Consumption Among HIV-Infected Women in a Randomized Controlled Trial of Naltrexone for Reducing Hazardous Drinking.

Authors:  Yan Wang; Xinguang Chen; Judith A Hahn; Babette Brumback; Zhi Zhou; Maria J Miguez; Robert L Cook
Journal:  Alcohol Clin Exp Res       Date:  2017-12-05       Impact factor: 3.455

2.  Alcohol Use and HIV Disease Progression in an Antiretroviral Naive Cohort.

Authors:  Judith A Hahn; Debbie M Cheng; Nneka I Emenyonu; Christine Lloyd-Travaglini; Robin Fatch; Starley B Shade; Christine Ngabirano; Julian Adong; Kendall Bryant; Winnie R Muyindike; Jeffrey H Samet
Journal:  J Acquir Immune Defic Syndr       Date:  2018-04-15       Impact factor: 3.731

3.  Phosphatidylethanol (PEth) as a Biomarker of Alcohol Consumption in HIV-Infected Young Russian Women: Comparison to Self-Report Assessments of Alcohol Use.

Authors:  Andrew K Littlefield; Jennifer L Brown; Ralph J DiClemente; Polina Safonova; Jessica M Sales; Eve S Rose; Nikolay Belyakov; Vadim V Rassokhin
Journal:  AIDS Behav       Date:  2017-07

4.  A utilitarian comparison of two alcohol use biomarkers with self-reported drinking history collected in antenatal clinics.

Authors:  Philip A May; Julie M Hasken; Marlene M De Vries; Anna-Susan Marais; Julie M Stegall; Daniel Marsden; Charles D H Parry; Soraya Seedat; Barbara Tabachnick
Journal:  Reprod Toxicol       Date:  2018-02-06       Impact factor: 3.143

5.  Reduction in Drinking was Associated With Improved Clinical Outcomes in Women With HIV Infection and Unhealthy Alcohol Use: Results From a Randomized Clinical Trial of Oral Naltrexone Versus Placebo.

Authors:  Robert L Cook; Zhi Zhou; Maria Jose Miguez; Clery Quiros; Luis Espinoza; John E Lewis; Babette Brumback; Kendall Bryant
Journal:  Alcohol Clin Exp Res       Date:  2019-07-10       Impact factor: 3.455

6.  Alcohol and Mortality: Combining Self-Reported (AUDIT-C) and Biomarker Detected (PEth) Alcohol Measures Among HIV Infected and Uninfected.

Authors:  Oghenowede Eyawo; Kathleen A McGinnis; Amy C Justice; David A Fiellin; Judith A Hahn; Emily C Williams; Adam J Gordon; Brandon D L Marshall; Kevin L Kraemer; Stephen Crystal; Julie R Gaither; E Jennifer Edelman; Kendall J Bryant; Janet P Tate
Journal:  J Acquir Immune Defic Syndr       Date:  2018-02-01       Impact factor: 3.731

7.  Point-of-Care Urine Ethyl Glucuronide Testing to Detect Alcohol Use Among HIV-Hepatitis B Virus Coinfected Adults in Zambia.

Authors:  Michael J Vinikoor; Zude Zyambo; Monde Muyoyeta; Geetanjali Chander; Michael S Saag; Karen Cropsey
Journal:  AIDS Behav       Date:  2018-07

8.  The Formation, Elimination, Interpretation, and Future Research Needs of Phosphatidylethanol for Research Studies and Clinical Practice.

Authors:  Judith A Hahn; Raymond F Anton; Martin A Javors
Journal:  Alcohol Clin Exp Res       Date:  2016-09-26       Impact factor: 3.455

9.  A randomized clinical trial of a group cognitive-behavioral therapy to reduce alcohol use among human immunodeficiency virus-infected outpatients in western Kenya.

Authors:  Rebecca K Papas; Benson N Gakinya; Michael M Mwaniki; Hana Lee; Alfred K Keter; Steve Martino; Debra A Klein; Tao Liu; Michelle P Loxley; John E Sidle; Kathryn Schlaudt; Tobista Nafula; Victor M Omodi; Joyce B Baliddawa; Daniel W Kinyanjui; Stephen A Maisto
Journal:  Addiction       Date:  2020-07-13       Impact factor: 6.526

10.  Secondary Analysis of a Randomized Clinical Trial of Naltrexone Among Women Living With HIV: Correlations Between Reductions in Self-Reported Alcohol Use and Changes in Phosphatidylethanol.

Authors:  Veronica L Richards; Ruba Sajdeya; Karina Villalba; Yan Wang; Vaughn Bryant; Babette Brumback; Kendall Bryant; Judith A Hahn; Robert L Cook
Journal:  Alcohol Clin Exp Res       Date:  2020-12-17       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.